

Disclosures

Personal Commercial (16)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Stock	Significant (>= \$5,000)	Prevention General Cardiology Invasive CV Angio and Interventions Vascular Medicine
AbbVie, Inc.	Stock	Significant (>= \$5,000)	General Cardiology
Amgen	Stock	Significant (>= \$5,000)	Prevention General Cardiology
Bristol-Myers Squibb	Stock	Significant (>= \$5,000)	General Cardiology Prevention
Cardinal Health	Stock	Significant (>= \$5,000)	Noninvasive Imaging
Eli Lilly and Company	Stock	Significant (>= \$5,000)	General Cardiology
General Electric	Stock	Modest (< \$5,000)	Noninvasive Imaging
INVIA Medical Imaging Solutions	Research/Research Grants	Significant (>= \$5,000)	Noninvasive Imaging
Ionetix	Consultant Fees/Honoraria	Significant (>= \$5,000)	Noninvasive Imaging
Medtronic	Stock	Significant (>= \$5,000)	Invasive CV Angio and Interventions
Merck	Stock	Significant (>= \$5,000)	Prevention General Cardiology
Mylan Laboratories	Stock	Modest (< \$5,000)	General Cardiology Prevention
Pfizer	Stock	Significant (>= \$5,000)	General Cardiology
Siemens	Research/Research Grants † Investigator initiated research grant	Significant (>= \$5,000)	Noninvasive Imaging
Singulex	Stock	Significant (>= \$5,000)	Noninvasive Imaging
Teva Pharmaceuticals	Stock	Modest (< \$5,000)	Prevention General Cardiology

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2019	Patent infringement	Defendant † Jubilant DRAXimage	Infringement of design of Rb-82 infusion system	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/20/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.